Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
about
Non-small cell lung cancer: current treatment and future advancesPemetrexed for advanced stage nonsquamous non-small cell lung cancer: latest evidence about its extended use and outcomesOvercoming resistance to first/second generation epidermal growth factor receptor tyrosine kinase inhibitors and ALK inhibitors in oncogene-addicted advanced non-small cell lung cancerSpotlight on pembrolizumab in non-small cell lung cancer: the evidence to dateClinical potential of necitumumab in non-small cell lung carcinomaChina Experts Consensus on the Diagnosis and Treatment of Advanced Stage Primary Lung Cancer (2016 Version)A critical review of recent developments in radiotherapy for non-small cell lung cancerLive cumulative network meta-analysis: protocol for second-line treatments in advanced non-small-cell lung cancer with wild-type or unknown status for epidermal growth factor receptorChemotherapy regimens for metastatic nonsmall cell lung cancer: Generating good quality data is important before challenging evidence.First-line treatment of NSCLC with bevacizumab: real world data from an Italian regional based survey.RICTOR polymorphisms affect efficiency of platinum-based chemotherapy in Chinese non-small-cell lung cancer patients.Safety profiles of non-small cell lung cancer patients treated with pemetrexed plus carboplatin: a real-world retrospective, observational, cohort study.Meta-analysis of pemetrexed plus carboplatin doublet safety profile in first-line non-squamous non-small cell lung cancer studies.Mutational status predicts the risk of thromboembolic events in lung adenocarcinomaMarked response to nab-paclitaxel in EGFR mutated lung neuroendocrine carcinoma: A case report.Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung CancerGeneration of novel patient-derived CIC- DUX4 sarcoma xenografts and cell lines.Third-generation epidermal growth factor receptor-tyrosine kinase inhibitors in T790M-positive non-small cell lung cancer: review on emerged mechanisms of resistance.PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancerComparison of Epidermal Growth Factor Receptor Mutations between Metastatic Lymph Node Diagnosed by EBUS-TBNA and Primary Tumor in Non-Small Cell Lung CancerDiagnostic Utility of Pleural Fluid Cell Block versus Pleural Biopsy Collected by Flex-Rigid Pleuroscopy for Malignant Pleural Disease: A Single Center Retrospective Analysis.Association of microRNA-33a Molecular Signature with Non-Small Cell Lung Cancer Diagnosis and Prognosis after Chemotherapy.Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data.[F-18] FDG-PET/CT parameters as predictors of outcome in inoperable NSCLC patients.Qualitative Development and Content Validity of the Non-small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC-SAQ), A Patient-reported Outcome Instrument.Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.Mutation testing for directing upfront targeted therapy and post-progression combination therapy strategies in lung adenocarcinoma.Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers.EGFR and KRAS Mutations Predict the Incidence and Outcome of Brain Metastases in Non-Small Cell Lung Cancer.Clinical and radiological features driving patient selection for antiangiogenic therapy in non-small cell lung cancer (NSCLC)Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.Targeting BET bromodomain proteins in solid tumorsRate of EGFR mutation testing for patients with nonsquamous non-small-cell lung cancer with implementation of reflex testing by pathologists.Comparison of outcomes of tyrosine kinase inhibitor in first- or second-line therapy for advanced non-small-cell lung cancer patients with sensitive EGFR mutations.Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine.Evaluation of the efficacy of cisplatin-etoposide and the role of thoracic radiotherapy and prophylactic cranial irradiation in LCNEC.Barriers to the Access of Bevacizumab in Patients with Solid Tumors and the Potential Impact of Biosimilars: A Physician Survey.Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trialA cost-effectiveness analysis of first-line induction and maintenance treatment sequences in patients with advanced nonsquamous non-small-cell lung cancer in France.
P2860
Q26740333-83ED337F-C381-4DAC-9758-9006D75FC537Q26745422-DB3C1CDA-9970-4F31-A99C-4F7FC8496306Q26745427-26AAF715-BAD3-435E-A18F-9F1A7A49C050Q28067610-68437D6F-E26B-4157-81E1-63CC6759540DQ28072850-870B4F17-E6D9-479B-B7A4-BF7AD43B35AEQ28073920-50FB4001-323C-4E79-B69F-ECA3F03AE661Q28079625-E9EE8838-5264-44B3-BD8B-D3E6A4B4DF0AQ28597805-2A555F74-0385-471E-8814-A521FAD15702Q31125762-2EC80B35-F16B-421B-8E63-F503C50FF2F6Q31133861-CF022B6D-49F6-4544-84ED-D4C334636FAEQ33435610-5578D16F-5589-41D8-8DF1-17E54FF7315CQ33439970-57E8B050-05C2-4FC6-BB28-F81E8477A3FDQ33439985-720E2878-CD6D-4605-A2E3-792C6B4E37A0Q33735646-A5B963C2-F5A3-45BD-B022-F1A69F67BF05Q33760613-0FBFF258-0226-4DD6-B274-29C839C2C971Q33873095-2CA27C5C-F0F8-4B15-9A4D-3C11560306B9Q33875284-C1F90540-6AF7-46DA-B54F-41FF4C1C08E8Q34550460-689FE8CA-AC8D-4733-ADA1-02A01FB70D88Q36103228-D5667025-A62D-470D-B688-1BA5C22BE8D7Q36148697-D15470E1-BF29-4B99-8CED-CDB78C34EABDQ36202696-D8DA46AF-B155-44E1-9D30-90F16E6F0D7CQ36264911-FDB66315-D8D0-47CE-9E4F-FBB85811B114Q36356699-50434FD2-AA12-49E7-8B0A-EEC3F0B572C2Q36363579-5A810152-60A3-4B17-A083-61634A633855Q36490370-8EAF8D01-7995-49D4-A8F2-DB79FBCD3D23Q36854048-DD5138F0-F6A9-4D3C-AFCC-A20BAC0645D9Q37041209-EF5A0E41-3B63-4C52-891D-11B4C0DC866CQ37051546-89989B0C-FCC3-4C5A-866A-ADB2B2EA9B46Q37264931-361A95FA-8B2B-4E51-B1A9-E67242582160Q37534932-2BB66CD8-17F5-4D1B-9F05-1EFFCE872948Q37539775-7BB9CABA-0B54-4CC3-9D7A-DA95B76654D3Q37569995-97E37D73-682B-4543-ACA2-944DB4DDB80DQ37619860-4D81F7D1-78FE-469D-84C3-CA9AF4C9CB90Q37672002-05B0E9FB-71AE-4116-8B8E-2F5B3B94E8A2Q37708814-1E002483-C396-4984-A812-B7BC5B537FA0Q37721218-99F208D8-EEA7-4A29-9D37-7694C5F254ACQ37725971-83F32FE9-95AB-437D-B4A8-CB107D2AB620Q37731321-038E6C81-3FC0-4969-9958-28D46FEE06F7Q38372645-9737BC4C-799F-41CD-806D-D6AB528EBBFAQ38598931-DCEF07FF-0C7D-45B1-BCF5-B2E1A676E30E
P2860
Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update
description
2015 nî lūn-bûn
@nan
2015 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@ast
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@en
type
label
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@ast
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@en
prefLabel
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@ast
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@en
P2093
P2860
P356
P1476
Systemic Therapy for Stage IV ...... ical Practice Guideline Update
@en
P2093
Ajeet Gajra
American Society of Clinical Oncology Clinical Practice
Christopher G Azzoli
David H Johnson
David Trent
Gregory A Masters
Joan H Schiller
John R Strawn
Julie R Brahmer
Nancy Rackear
P2860
P304
P356
10.1200/JCO.2015.62.1342
P407
P577
2015-08-31T00:00:00Z